Dayah Capital LLC Purchases Shares of 48,073 Ingevity Corporation $NGVT

Key Points

• Dayah Capital acquired 48,073 Ingevity shares worth approximately $3.59 million, representing 0.14% of the company and 1.2% of the fund’s portfolio. Overall, institutional investors own 91.59% of Ingevity.
• Ingevity’s latest quarterly results exceeded expectations, with EPS of $1.74 versus the $1.33 consensus estimate and revenue of $314.1 million. The company issued fiscal 2026 EPS guidance of $5.00–$5.45.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $80.00. Meanwhile, company insiders sold 18,297 shares worth roughly $1.38 million during the last quarter.

Dayah Capital LLC purchased a new stake in Ingevity Corporation (NYSE:NGVT - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,073 shares of the company's stock, valued at approximately $3,590,000. Ingevity comprises 1.2% of Dayah Capital LLC's investment portfolio, making the stock its 13th biggest position. Dayah Capital LLC owned approximately 0.14% of Ingevity at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Primecap Management Co. CA acquired a new position in shares of Ingevity during the 2nd quarter worth approximately $5,152,000. Palisade Capital Management LP purchased a new position in Ingevity during the second quarter worth $17,511,000. Canada Pension Plan Investment Board acquired a new position in shares of Ingevity in the second quarter worth $1,113,000. Legal & General Group Plc acquired a new position in shares of Ingevity in the second quarter worth $6,082,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Ingevity in the second quarter valued at $1,305,000. 91.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NGVT has been the subject of several analyst reports. Weiss Ratings raised shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Ingevity has a consensus rating of "Hold" and an average price target of $80.00.

Ingevity Stock Performance

NYSE NGVT opened at $69.08 on Wednesday. The business's 50-day moving average price is $73.72 and its 200 day moving average price is $71.84. Ingevity Corporation has a twelve month low of $45.85 and a twelve month high of $79.29. The company has a market capitalization of $2.38 billion, a PE ratio of 46.99 and a beta of 1.16. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52.

Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The company had revenue of $314.10 million during the quarter, compared to analysts' expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, research analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO David H. Li sold 5,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the sale, the chief executive officer directly owned 120,636 shares in the company, valued at $9,147,827.88. This represents a 3.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total value of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. This trade represents a 14.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 18,297 shares of company stock valued at $1,381,452 over the last quarter. Company insiders own 0.88% of the company's stock.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.